Advertisement

Menopause, HRT, and Hemostasis

  • P. G. Crosignani
  • C. Boschetti
  • M. Cortellaro
  • M. Meschia
Part of the Medical Science Symposia Series book series (MSSS, volume 11)

Abstract

Clotting factors play an important role in the pathophysiology of cardiovascular disease (CVD). In fact, plasma fibrinogen concentration is directly associated with the incidence of CVD [1], while a 1% decrease in factor VII (FVII) activity leads to a 2% reduction in the risk of death from coronary heart disease [2].

Keywords

Hormone Replacement Therapy Medroxyprogesterone Acetate Fibrinogen Plasma Level Oral Estrogen Plasma Fibrinogen Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ernst E. Fibrinogen: An important risk factor for atherothrombotic diseases. Ann Med 1994;26:15–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986;ii:533–37.CrossRefGoogle Scholar
  3. 3.
    Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status. Influence of hormone replacement therapy. Thromb Haemost 1993;70:584–87.PubMedGoogle Scholar
  4. 4.
    Meade TW, Dyer S, Howarth DJ, Jamieson JD, Stirling Y. Antithrombin III and procoagulant activity: Sex differences and effects of the menopause. Br J Haematol 1990;74:77–81.PubMedCrossRefGoogle Scholar
  5. 5.
    The writing group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199–208.CrossRefGoogle Scholar
  6. 6.
    Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biological effects of transdermal estradiol. N Engl J Med 1986;314:1615–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Alkjaersig N, Fletcher AP, De Ziegler D, Steingold KA, Meldrum DR, Judd HL. Blood coagulation in postmenopausal women given estrogen treatment: Comparison of transdermal and oral administration. J Lab Clin Med 1988;111:224–28.PubMedGoogle Scholar
  8. 8.
    Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Delia Volpe A, Zanussi C. Short-and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res 1991;62:1–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Fox J, George AJ, Newton JR, et al. Effect of transdermal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993;18:55–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994;71:420–23.PubMedGoogle Scholar
  11. 11.
    The writing group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study. Thrombosis and Haemostasis 1996;75:476–80.Google Scholar
  12. 12.
    Nabulsi AA, Folsom AR, White A, et al. for the Atherosclerosis Risk in Communities Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069–75.PubMedCrossRefGoogle Scholar
  13. 13.
    Lobo AA, Pickard JH, Wild RA, Walsh B, Hirvonen E for the Menopause Study Group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994;84:987–95.PubMedGoogle Scholar
  14. 14.
    Daly E, Vessey MP, Hawkins MH, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983–87.PubMedCrossRefGoogle Scholar
  17. 17.
    Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet 1991;338:850–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Cortellaro M. Antithrombin III and arterial disease. Lancet 1991;338:1525–26.PubMedCrossRefGoogle Scholar
  19. 19.
    Conlan MG, Folsom AR, Finch A, et al. Antithrombin III: Associations with age, race, sex and cardiovascular disease risk factors. Thromb Haemost 1994;72:551–56.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1997

Authors and Affiliations

  • P. G. Crosignani
  • C. Boschetti
  • M. Cortellaro
  • M. Meschia

There are no affiliations available

Personalised recommendations